
This graphical abstract illustrates how by identifying and keeping track of key disconnections essential to patent protected syntheses, a retrosynthetic computer program can autonomously design synthetic routes, ”navigating around” previously published or patented approaches.
CREDIT
Molga et al./Chem
Routes to making life-saving medications and other pharmaceutical compounds are among the most carefully protected trade secrets in global industry. Building on recent work programming computers to identify synthetic pathways leading to pharmaceutically complex molecules, researchers in Poland and South Korea have unveiled computerized methods to suggest only synthetic strategies that bypass patent-protected aspects of essential drugs.
Their work appears January 17 in the journal Chem.
“When we started this project, I was somewhat skeptical that the machine would find any viable synthetic alternatives–after all, these are blockbuster drugs worth gazillions of dollars, and I was sure that the respective companies had covered the patent space so densely that no loopholes remained,” says senior author Bartosz Grzybowski, a professor of chemistry at the Ulsan National Institute of Science and Technology (South Korea) and the Polish Academy of Sciences and the lead developer of the organic synthesis software Chematica. “It turns out that the loopholes are there, and we can find new retrosynthetic pathways that circumvent the patents entirely.”
Those pharmaceutical patents protect the company’s intellectual property while also preventing competitor companies from using certain key synthetic solutions–developed painstakingly by experiment to maximize yield, increase purity, and reduce costs–when attempting to produce desired compounds. To get to viable unpatented options, the researchers “froze” challenging portions of each target molecule, forcing the computer to substitute unconventional yet chemically plausible approaches on the basis of mechanistic rules. They tested their system out on three notable commercial medicines with different chemical hurdles: linezolid, a last-resort antibiotic; sitagliptin, an antidiabetic drug; and panobinostat, a multiple myeloma treatment.
In each case, when allowed to run without constraints, the program recommended the commercial syntheses. But when even a few atoms and bonds were designated as untouchable, it innovated by applying Chematica’s existing functions to propose new plans that neatly avoided those already patented. “By algorithmically locating the key bonds on which patents hinge and propagating them down Chematica’s retrosynthetic trees, we can generate synthetic solutions from alternative yet economical starting materials, achieving a real practical impact,” Grzybowski says.
Chematica’s patent-dodging abilities could also alter how chemists approach intellectual property and patent law. For example, machine-aided searches could be used to restrict many different parts of a target molecule, lumping radically different syntheses into a single airtight patent. According to Grzybowski, however, such a patent would not necessarily stay loophole-free forever, thanks to the likely future experimental discovery of novel reactions driving chemical knowledge forward through healthy competition.
Overall, the researchers hope that their software will aid pharmaceutical companies in better protecting their intellectual property and, simultaneously, will help accelerate research and development in organic chemistry by supplying synthetic routes that differ from standard approaches. “This work illustrates the benefits of pushing chemists to think algorithmically and asking computer scientists to grasp key chemical concepts, delivering chemical artificial intelligence results that matter beyond the confines of academia,” adds co-author Piotr Dittwald, a research fellow with training in mathematics and computer science.
Learn more: This computer program makes pharma patents airtight
The Latest on: Pharma patents
via Google News
The Latest on: Pharma patents
- Want to bet on Big Pharma? M&A hunger, pricing pressure increase the risk, ratings agency sayson February 24, 2021 at 9:41 am
Big Pharma companies have been steadily dropping in the eyes of credit ratings agencies since 2014. That downward spiral won’t likely end in 2021, thanks to the industry’s unrelenting appetite for M&A ...
- Top 15 Pharmaceutical Companies With Highest R&D Spendingon February 24, 2021 at 6:31 am
In this article we are going to list the top 15 pharmaceutical companies with the highest R&D spending. Click to skip ahead and jump to the Top ...
- United States Diabetes Drug Market Report 2021-2026: Dosage, Formulation, Patent, Pricing Insight by Drug Classon February 24, 2021 at 5:12 am
The "US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026" report has been added to ResearchAndMarkets.com's offering. As per the "US Diabetes Drug Market, Dosage, Price, Sales Insight ...
- OKYO Pharma gets US patent for lipid conjugated peptide analogues to treat ocular pain and inflammationon February 24, 2021 at 1:30 am
OKYO Pharma gets US patent for lipid conjugated peptide analogues to treat ocular pain and inflammation: London Wednesday, February 24, 2021, 15:00 Hrs [IST] OKYO Pharma, a biotec ...
- Health Over Profit: Why Pharma Companies Should Share Their Vaccine Patentson February 23, 2021 at 9:06 pm
A lot of tax money goes into researching covid vaccines, but the profits are only cashed in by the pharma industry. For the sake of profit, pharmaceutical companies keep their patents under wraps, ...
- OKYO Pharma higher after receiving ocular pain treatment patenton February 23, 2021 at 5:09 am
OKYO Pharma Limited (LON:OKYO) climbed 6.9% to 9.75p after it was issued a US patent. The biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and chronic ...
- Sun Pharma launches Belgian firm UCB epilepsy drug after patent expiryon February 23, 2021 at 3:56 am
Sun Pharmaceutical Industries has launched anti-epileptic drug Brivaracetam in multiple dosage forms, at an “affordable” price, the company said, without giving details.It’s brand Brevipil tablet was ...
- OKYO Pharma receives US patent covering 'secret sauce' of a potential new class of pain relief drugon February 23, 2021 at 3:38 am
The protection covers a class of bovine adrenal medulla (BAM) peptides linked to certain lipids that OKYO’s scientists think may have therapeutic potential ...
- OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammationon February 22, 2021 at 11:00 pm
OKYO Pharma Limited, a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and chronic ocular pain, today announced that patent No. 10,899,796 entitled“ ...
- Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidateon February 17, 2021 at 6:00 am
Adamis Pharmaceuticals Corporation today announced that it recently received a notice that one of its patent applications relating to its ZIMHI™ high dose naloxone injection product candidate, ...
via Bing News